The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. We may also receive compensation if you click on certain links posted on our site. We may receive compensation from our partners for placement of their products or services. While we are independent, the offers that appear on this site are from companies from which receives compensation. Sumitomo Pharma Co.į is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. It has licensing and collaboration agreements with Zymeworks Inc. coli-derived asparaginase Vyxeos, a liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia and Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation. The company's lead marketed products in oncology comprise Zepzelca for the treatment of adult patients with metastatic small cell lung cancer Rylaze, a product for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adults and pediatric patients aged one month or older who has developed hypersensitivity to E. Its lead marketed products in neuroscience include Xywav, an oral solution for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy and idiopathic hypersomnia (IH) Xyrem, a sodium oxybate oral solution for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older and Epidiolex, a cannabidiol oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients one year of age or older. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders and in oncology, such as hematologic and solid tumors. Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. This would suggest that Jazz Pharmaceuticals's shares are less volatile than average (for this exchange).
The market (NASDAQ average) beta is 1, while Jazz Pharmaceuticals's is 0.7412. volatility (beta: 1.00) Low Highīeta is a measure of a share's volatility in relation to the market. A popular way to gauge a stock's volatility is its "beta". Over the last 12 months, Jazz Pharmaceuticals's shares have ranged in value from as little as $124.58 up to $163.31. Jazz Pharmaceuticals share price volatility We're not expecting Jazz Pharmaceuticals to pay a dividend over the next 12 months. TTM: trailing 12 months Jazz Pharmaceuticals share dividends
Jazz Pharmaceuticals financials Revenue TTM All international money transfer services.
0 kommentar(er)
